GYRE vs SLBT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GYRE · Gyre Therapeutics$4.76 ▲ 18.70%
SLBT · SL Science$0.94 ▲ 4.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GYRE -39.9%
- SLBT -91.0%
Head to head
| Metric | GYRE | SLBT |
|---|---|---|
| Price | $4.76 | $0.94 |
| Change today | ▲ 18.70% | ▲ 4.16% |
| Market cap | $504.72M | $525.71M |
| Return, 3 months | -29.2% | -66.9% |
| Return, year to date | -32.6% | -91.1% |
| Return, 1 year | -34.0% | -91.0% |
| P/E (TTM) | – | – |
| P/B | 4.7 | 78.1 |
| P/E percentile vs own 5y | 10th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -2.1% | -34.7% |
| Net profit growth (YoY) | -537.9% | -220.6% |
| Gross margin | 93.8% | 38.4% |
| Operating margin | -13.9% | -178.8% |
| Net margin | -18.1% | -178.4% |
| Return on equity | -19.9% | -74.9% |
| Analyst target vs. price | +299.2% | – |
| Analyst buy share | 100% | – |
| RSI (14) | 38 | 26 |
| 30-day volatility | 130.2% | 111.8% |
| Max drawdown, 1 year | -54.2% | -93.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLBT is the largest of the group by market value.
- GYRE has returned the most over the past year.
- GYRE is growing revenue fastest.
- GYRE keeps the most profit per dollar of sales.
- SLBT has been the calmest stock over the last 30 days.